Vaccine Research Study
Researchers at NYU Langone Health are conducting a clinical research study to learn more about an investigational pneumococcal vaccine in adults ages 65 to 84.
Fast Facts
Have Never Received a Pneumococcal Vaccine OR Received The Pneumovax 23 Vaccine Over 5 Years Ago
Adults Aged 65–84
Compensation
Provided Up To $1275
Conducted in
New York, NY
Study Background
This research study is evaluating the safety of an investigational pneumococcal vaccine and how well it helps the immune system respond to pneumococcal disease.
Pneumococcal disease is caused by the bacteria Streptococcus pneumoniae and can lead to serious infections such as pneumonia, bloodstream infections, and meningitis—especially in older adults. Vaccines play an important role in preventing pneumococcal disease, and researchers continue to study new vaccine options that may improve protection.
This study will help researchers understand whether an investigational pneumococcal vaccine is safe and whether it produces an immune response that may help protect against pneumococcal disease. The study will be conducted at the NYU Langone Vaccine Center in Manhattan and will involve multiple study visits over approximately 14 to 18 months. All study-related care is provided by experienced infectious disease specialists.
Study Background
This research study is evaluating the safety of an investigational pneumococcal vaccine and how well it helps the immune system respond to pneumococcal disease.
Pneumococcal disease is caused by the bacteria Streptococcus pneumoniae and can lead to serious infections such as pneumonia, bloodstream infections, and meningitis—especially in older adults. Vaccines play an important role in preventing pneumococcal disease, and researchers continue to study new vaccine options that may improve protection.
This study will help researchers understand whether an investigational pneumococcal vaccine is safe and whether it produces an immune response that may help protect against pneumococcal disease. The study will be conducted at the NYU Langone Vaccine Center in Manhattan and will involve multiple study visits over approximately 14 to 18 months. All study-related care is provided by experienced infectious disease specialists.
Additional Information
This study is being done to evaluate the safety of an investigational pneumococcal vaccine and to see how well it helps the body produce an immune response against pneumococcal disease.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Adults ages 65-84
- Have never received a pneumococcal vaccine OR received the Pneumovax 23 vaccine over 5 years ago
- Live in New York
- BMI between 18-35
- Have not received a shingles, Novavax COVID, or hepatitis B vaccine within the last year
Exclusion Criteria:
- Immunodeficiencies such as malignancy, HIV infection, organ or stem cell transplant
- History of pneumococcal disease (infection caused by Streptococcus pneumoniae)
- Major or unstable medical conditions
- History of substance abuse issues
If you choose to participate:
You will complete a phone screening to see if you may be eligible.
You will attend 9 in-person study visits at the NYU Langone Vaccine Center over 14–18 months.
At study visits, staff will review your medical and vaccine history and collect blood samples.
You will receive two injections of either the study vaccine or a placebo, given on either a 0- and 2-month schedule or a 0- and 6-month schedule.
After each vaccination, study staff will check in on your health, and you will complete brief questions using an electronic diary (on a device or mobile phone app).
Participants are compensated for their time and participation:
$125 per study visit
$75 for completion of the electronic diary after each vaccination
$50 for additional blood draws (if applicable)
Total compensation of up to $1,275
There is no cost to participate. Transportation reimbursement may be provided. Participants will also receive amenities such as snacks or meals, coffee, water, and blankets during study visits.
There is no cost for you to participate in our research study.